Table of Contents
Thrombosis
Volume 2010 (2010), Article ID 540386, 9 pages
http://dx.doi.org/10.1155/2010/540386
Clinical Study

Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis

1Department of Pulmonary/Critical Care/Sleep Medicine, Walter Reed Army Medical Center, Pulmonary/Sleep and Critical Care Service, 6900 Georgia Avenue NW, Washington, DC 20307, USA
2Department of Pulmonary/Critical Care Medicine, William Beaumont Army Medical Center, 5005 N. Piedras Street, El Paso, TX 79930, USA
3Department of Medicine, The Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814, USA

Received 4 October 2010; Accepted 15 November 2010

Academic Editor: Paolo Simioni

Copyright © 2010 Aaron B. Holley et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. H. White, “The epidemiology of venous thromboembolism,” Circulation, vol. 107, supplement 1, no. 23, pp. I4–I8, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota, “Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition),” Chest, vol. 133, no. 6, supplement 6, pp. 454S–545S, 2008. View at Publisher · View at Google Scholar · View at PubMed
  3. C. Kearon, “Indefinite anticoagulation after a first episode of unprovoked venous thromboembolism: yes,” Journal of Thrombosis and Haemostasis, vol. 5, no. 12, pp. 2330–2335, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. T. Baglin, “Unprovoked deep vein thrombosis should be treated with long-term anticoagulation—no,” Journal of Thrombosis and Haemostasis, vol. 5, no. 12, pp. 2336–2339, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. H. R. Büller, G. Agnelli, R. D. Hull, T. M. Hyers, M. H. Prins, and G. E. Raskob, “Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy,” Chest, vol. 126, no. 3, supplement, pp. 401S–428S, 2004. View at Publisher · View at Google Scholar
  6. G. Agnelli, P. Prandoni, C. Becattini et al., “Extended oral anticoagulant therapy after a first episode of pulmonary embolism,” Annals of Internal Medicine, vol. 139, no. 1, pp. 19–I51, 2003. View at Google Scholar · View at Scopus
  7. G. Agnelli, P. Prandoni, M. G. Santamaria et al., “Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis,” The New England Journal of Medicine, vol. 345, no. 3, pp. 165–169, 2001. View at Publisher · View at Google Scholar · View at PubMed
  8. V. Snow, A. Qaseem, P. Barry et al., “Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians,” Annals of Internal Medicine, vol. 146, no. 3, pp. 204–210, 2007. View at Google Scholar
  9. D. Ost, J. Tepper, H. Mihara, O. Lander, R. Heinzer, and A. Fein, “Duration of anticoagulation following venous thromboembolism: a meta-analysis,” Journal of the American Medical Association, vol. 294, no. 6, pp. 706–715, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. B. A. Hutten and M. H. Prins, “Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD001367, 2006. View at Google Scholar
  11. J. B. Segal, M. B. Streiff, L. V. Hofmann, K. Thornton, and E. B. Bass, “Management of venous thromboembolism: a systematic review for a practice guideline,” Annals of Internal Medicine, vol. 146, no. 3, pp. 211–222, 2007. View at Google Scholar · View at Scopus
  12. L. Pinede, J. Ninet, P. Duhaut et al., “Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis,” Circulation, vol. 103, no. 20, pp. 2453–2460, 2001. View at Google Scholar · View at Scopus
  13. I. A. Campbell, D. P. Bentley, R. J. Prescott, P. A. Routledge, H. G. M. Shetty, and I. J. Williamson, “Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial,” British Medical Journal, vol. 334, no. 7595, pp. 674–677, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. D. Keeling, “Duration of anticoagulation: decision making based on absolute risk,” Blood Reviews, vol. 20, no. 3, pp. 173–178, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. R. Vink, R. A. Kraaijenhagen, M. Levi, and H. R. Büller, “Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model,” Journal of Thrombosis and Haemostasis, vol. 1, no. 12, pp. 2523–2530, 2003. View at Google Scholar · View at Scopus
  16. A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. S. G. Thompson and S. J. Sharp, “Explaining heterogeneity in meta-analysis: a comparison of methods,” Statistics in Medicine, vol. 18, no. 20, pp. 2693–2708, 1999. View at Google Scholar · View at Scopus
  18. B. Cosmi, C. Legnani, A. Tosetto et al., “Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study,” Journal of Thrombosis and Thrombolysis, vol. 28, no. 4, pp. 381–388, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. G. Palareti, B. Cosmi, C. Legnani et al., “D-dimer testing to determine the duration of anticoagulation therapy,” The New England Journal of Medicine, vol. 355, no. 17, pp. 1780–1789, 2006. View at Publisher · View at Google Scholar · View at PubMed
  20. R. S. Farraj, “Anticoagulation period in idiopathic venous thromboembolism. How long is enough?” Saudi Medical Journal, vol. 25, no. 7, pp. 848–851, 2004. View at Google Scholar · View at Scopus
  21. S. Schulman, A. S. Rhedin, P. Lindmarker et al., “A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism,” The New England Journal of Medicine, vol. 332, no. 25, pp. 1661–1665, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. P. A. Kyrle, E. Minar, C. Bialonczyk, M. Hirschl, A. Weltermann, and S. Eichinger, “The risk of recurrent venous thromboembolism in men and women,” The New England Journal of Medicine, vol. 350, no. 25, pp. 2558–2631, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. D. Poli, E. Antonucci, G. Ciuti, R. Abbate, and D. Prisco, “Combination of D-dimer, F1+2 and residual vein obstruction as predictors of VTE recurrence in patients with first VTE episode after OAT withdrawal,” Journal of Thrombosis and Haemostasis, vol. 6, no. 4, pp. 708–710, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. C. Legnani, S. Mattarozzi, M. Cini, B. Cosmi, E. Favaretto, and G. Palareti, “Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal,” British Journal of Haematology, vol. 134, no. 2, pp. 227–232, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. G. Palareti, C. Legnani, B. Cosmi et al., “Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia,” Circulation, vol. 108, no. 3, pp. 313–318, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. C. Kearon, M. Gent, J. Hirsh et al., “A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism,” The New England Journal of Medicine, vol. 340, no. 12, pp. 901–907, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. P. M. Ridker, S. Z. Goldhaber, E. Danielson et al., “Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism,” The New England Journal of Medicine, vol. 348, no. 15, pp. 1425–1434, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. T. Baglin, R. Luddington, K. Brown, and C. Baglin, “Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study,” The Lancet, vol. 362, no. 9383, pp. 523–526, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. M. Verhovsek, J. D. Douketis, Q. Yi et al., “Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism,” Annals of Internal Medicine, vol. 149, no. 7, pp. 481–490, 2008. View at Google Scholar · View at Scopus